Navigation Links
Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
Date:9/28/2010

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Hypertension reveal that the market-leading drug, Novartis's Diovan/Tareg, will suffer the greatest decline as its sales will decrease more than $1 billion in 2013, following the entry of generic versions of the drug. By 2019, the drug classes typically used as first-, second-, and third-line therapy will all be subject to generic competition — these drug classes are the angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRA), calcium channel blockers (CCBs) and diuretics.

"Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic antihypertensive drugs," said Decision Resources Analyst Taskin Ahmed. "Through 2019, we do not forecast blockbuster sales for any of the emerging antihypertensive agents."

The Pharmacor 2010 findings also reveal that, although the overall market will decline, sales of therapies offering greater convenience, such as fixed-dose combinations, will increase over the next several years. The CCB/ renin-angiotensin-aldosterone system (RAAS) inhibitor fixed-dose combinations and CCB/RAAS inhibitor/diuretic fixed-dose combinations will capitalize on this opportunity, generating approximately $6 billion in total sales in 2019.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
7. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... JOHNSTON, Iowa (PRWEB) , ... October 12, 2017 ... ... company based in Vilnius, Lithuania, announced today that they have entered into a ... collaboration is to provide CRISPR researchers with additional tools for gene editing across ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):